Integral Diagnostics (ASX:IDX) Debt-to-Equity : 1.20 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Integral Diagnostics Debt-to-Equity?

Integral Diagnostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$17.9 Mil. Integral Diagnostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$343.6 Mil. Integral Diagnostics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$300.4 Mil. Integral Diagnostics's debt to equity for the quarter that ended in Dec. 2023 was 1.20.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Integral Diagnostics's Debt-to-Equity or its related term are showing as below:

ASX:IDX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.7 Med: 0.98 Max: 1.31
Current: 1.2

During the past 8 years, the highest Debt-to-Equity Ratio of Integral Diagnostics was 1.31. The lowest was 0.70. And the median was 0.98.

ASX:IDX's Debt-to-Equity is ranked worse than
87.31% of 197 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22 vs ASX:IDX: 1.20

Integral Diagnostics Debt-to-Equity Historical Data

The historical data trend for Integral Diagnostics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integral Diagnostics Debt-to-Equity Chart

Integral Diagnostics Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

1.09

1.22

1.21

0.98

Integral Diagnostics Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial												1.31	0.98	0.98	0.98	1.20

Competitive Comparison of Integral Diagnostics's Debt-to-Equity

For the Diagnostics & Research subindustry, Integral Diagnostics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Integral Diagnostics's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Integral Diagnostics's Debt-to-Equity falls into.

Integral Diagnostics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Integral Diagnostics's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(16.668	+	348.408)	/	373.048
	=	0.98

Integral Diagnostics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(17.883	+	343.609)	/	300.375
	=	1.20

Integral Diagnostics (ASX:IDX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Integral Diagnostics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Integral Diagnostics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Integral Diagnostics (ASX:IDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Integral Diagnostics Ltd (ASX:IDX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ITGDF:USA

Address

45 William Street, Suite 9.02, Level 9, Melbourne, VIC, AUS, 3000

Website

http://www.integraldiagnostics.com.au

Integral Diagnostics is Australia's fourth-largest diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.